HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the... |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
SUTENT® (sunitinib malate)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
SUTENT® Quick Finder
WARNING: HEPATOTOXICITY
Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see...
1 INDICATIONS AND USAGE
1.1 Gastrointestinal Stromal Tumor
SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after...
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage for GIST and Advanced RCC
The recommended dosage of SUTENT for gastrointestinal stromal tumor (GIST) and advanced...
3 DOSAGE FORMS AND STRENGTHS
Capsules, hard gelatin:
- 12.5 mg sunitinib: orange cap and orange body, printed with white ink "Pfizer" on the cap and "STN 12.5 mg" on the body.
- 25 mg sunitinib:...
5 WARNINGS AND PRECAUTIONS
5.1 Hepatotoxicity
SUTENT can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver...
6 ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling.
- Hepatotoxicity [see Warnings and Precautions (...
7 DRUG INTERACTIONS
7.1 Effect of Other Drugs on SUTENT
Strong CYP3A4 Inhibitors
...8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on animal...
10 OVERDOSAGE
Treatment of overdose with SUTENT should consist of general supportive measures. There is no specific antidote for overdosage with SUTENT. If indicated, elimination of unabsorbed drug should be achieved by...
11 DESCRIPTION
Sunitinib is a kinase inhibitor present in SUTENT capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with ...
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated...
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2...
14 CLINICAL STUDIES
14.1 Gastrointestinal Stromal Tumor
Study 1
Study 1 (NCT#...
16 HOW SUPPLIED/STORAGE AND HANDLING
SUTENT 12.5 mg capsules are supplied as hard gelatin capsule with orange cap and orange body, printed with white ink "Pfizer" on the cap, "STN 12.5 mg" on the body:
...This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: August 2021 | ||
MEDICATION GUIDE... |
Resources
To interact with the Medical Information Digital Assistant click here.
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.